The new IP battleground in CRISPR-Cas
While much attention has been focused on the major IP battle affecting foundational patents covering CRISPR-Cas9 systems as gene modifiers, another battle has erupted concerning modified guide ribonucleic acids (RNAs) for use with Cas enzymes. The most visible recent sign of this was the invalidation of all claims of two US Patents of Agilent, US10,900,034 and US10,337,001, by a Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) in inter partes review proceedings instigated by Synthego.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk